T hrombolytic intervention with or without coronary angioplasty is becoming widely accepted as standard therapy for patients who present early with acute myocardial infarction, Thrombolytic therapy has been shown to improve left ventricular function* and reduce mortality.2 Nearly all clinical trials of myocardial reperfusion have excluded patients with a history of coronary artery bypass grafting. Furthermore, the only available data for the use of thrombolytic agents in this patient group consist of case reports of intracoronary thrombolytic agents3 and a small series of intravenous thrombolytic agents4 There are no published data for the use of angioplasty or combined thrombolysis and angioplasty in patients with acute infarction after bypass surgery. Considering the increasing number of patients undergoing coronary artery bypass grafting and their propensity for future cardiac events,5 important questions regarding the optimal treatment strategy for prior coronary artery bypass patients come to bear. Accordingly, we reviewed our experience in the treatment of patients after coronary artery bypass surgery in the setting of evolving myocardial infarction.
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Records from the University of Michigan Cardiac Catheterization Laboratory were reviewedfrom January I, 1984 I, , to December 30, 1987 , and a database of patients with a history of coronary artery bypass grafting and acute myocardial infarction was tabulated. Acute myocardial infarction was diagnosed when an episode of characteristic chest pain lasting 130 minutes was associated with a transient, temporally appropriate increase of the total serum creatine phosphokinase above the upper limit of normal with myocardial isoenzyme fraction greater than twice normal. Data were compiled regarding the presence and type of standard electrocardio- were saphenous vein grafts (54%). Left internal thoracic artery grafts were not present in any of our patients. Acute intervention was attempted in 20 of these patients in whom the infarct-related vessel could be ascertained.
The time from onset of symptoms to intervention was 4 f 1 hours (range 2 to 6).
Intravenous thrombolysis was only used in 4 (10%) of the patients (100 mg of recombinant tissue plasminogen activator in 2 cases, 1.5 million U of intravenous streptokinase in 1 case and 500,000 U of urokinase in 1 case) and was successful in establishing vessel patency in 3 (75%). The infarct-related artery of the patient with unsuccessful reperfusion was a native right coronary artery. Direct coronary angioplasty of the infarct-related vessel was performed in 9 patients (23%) and vessel patency was achieved in 7 (78%). The 2 unsuccessful coronary angioplasties were in saphenous vein grafts, 1 to the left anterior descending artery and 1 to an obtuse marginal branch. Combined angioplasty and thrombolytic therapy (intracoronary urokinase or streptokinase) was performed in 7 patients and resulted in reperfusion in 6 (86%). The unsuccessful combined therapy was in a patient with a native right coronary as the infarct-related vessel. Angiographically demonstrable embolic complications were not noted. The total success rate of all acute interventions in establishing infarct-related vessel patency was 16 of 20 (80% emergency repeat coronary artery bypass grafting and the remaining 18 were treated medically. Four patients died in the hospital (10%). Two of these patients had been treated medically; 1 died during emergency repeat coronary artery bypass surgery and the other died during acute coronary angioplasty (without combined thrombolysis). The intermediate-term postdischarge outcome was available in 38 of 40 patients. There were 4 deaths within thefirst 3 months, 3 in patients who had been treated medically and I by acute intervention with angioplasty only. Five patients had repeat coronary artery bypass grafting, 2 of whom had been treated medically, 2 by angioplasty only and 1 by combined thrombolysis and angioplasty. Eight patients had further revascularization by coronary angioplasty. Three of the 4 patients treated by thrombolysis alone had angioplasty of a residual stenosis of the infarctrelated vessel. Two patients from the group initially treated with combined angioplasty and thrombolysis had restenosis of the infarct-related artery of which one was successfully dilated. One other patient from the combined treatment group had a delayed angioplasty of a noninfarct-related artery. Two patients in the medically treated group had delayed angioplasties; 1 was successful. Thus, 8 of 20 patients (40%) initially treated with acute intervention went on to have successful revascularization procedures after their acute infarct; I was lost to follow-up and 1 died. The remainder had patent infarct-related arteries at recatheterization or were asymptomatic clinically.
The number of patients undergoing coronary artery bypass grafting with saphenous vein grafts has been steadily increasing.' Considering that the rate of late graft occlusion is approximately 4%/year8 and the yearly rate of myocardial infarction after coronary artery bypass surgery is approximately ~'SJ,~ the number of patients at risk for these events continues to increase. Thus, this group of patients represents an increasing proportion of cases of acute myocardial infarction that may benefit from acute intervention. However, the experience on the use of thrombolytic agents or angioplasty in these patients remains very limited.
This study reports our experience in patients after coronary artery bypass grafting in the setting of acute myocardial infarction. Although the number of patients available for review is small when compared to large scale clinical trials, it represents a large series of such patients reported to date. Furthermore, we report all such patients presenting to our institution regardless of whether or not an intervention was performed.
We noted a limited ability of the standard electrocardiogram to corroborate acute myocardial infarction and aid in ability to determine the infarct area. The preponderance of non-Q-wave myocardial infarcts in our study probably relates to either the finding that the infarctrelated vessel is less likely to be a main epicardial arterylo or to the presence of collaterals. Thus, such infarcts are usually smaller in postcoronary artery bypass surgery patients." This observation may impede the ability to promptly intervene in these patients when they present with acute myocardial infarction.
Furthermore, even with angiography the infarctrelated vessel could not be reliably identified in a fairly large proportion of our patients. This phenomenon was due to the presence of >l vessel occlusion or multiple discordant wall motion abnormalities. With our concern over patient safety intervention with direct angioplasty or intracoronary thrombolysis was not possible in this group.
However, in our patients in whom the infarct-related vessel could be ascertained and acute intervention was performed, the results as assessed by vessel patency compared less favorably with a cohort of patients who never had bypass surgery. Although the lesions encountered in these patients may have been somewhat more "resistant" to thrombolytic therapy or angioplasty, there was yet a high degree of success. We did not encounter overt angiographic evidence of embolic complications as reported by others.12 Furthermore, more definitive revascularization with redo surgery was then possible in many of these patients at a later date. The limited number of patients in our study preclude recommendations as to the general treatment of such patients. However, based on this experience acute intervention in this setting is a viable option, albeit with a decreased reperfusion success rate, but with a potentially positive impact on the prognosis of these patients. There appears to be no legitimate reason to exclude this important group of patients from prospective reperfusion trials. T he anaerobic threshold is the submaximal level of exertion above which lactic acid progressively accumulates in the blood and fatigue progressively increases during incremental exercise. lv2 The anaerobic threshold is a useful clinical measurement of submaximal exercise performance in normal subjects1-3 and in patients with congestive heart failure,4 angina pect0ri.G and valvular regurgitation,6 and has been used to assess drug interventions.' In patients with effort angina, ST-segment depres- sion is reduced and exercise time increased after calcium antagonists.8y9 If relief of myocardial ischemia by verapamil allows an improvement in peak oxygen consumption (VO@&), there may also be an improvement in oxygen metabolism by exercising muscle and the anaerobic threshold may increase, delaying the onset of fatigue. This study determines whether verapamil alters the oxygen consumption (VO2) at the anaerobic threshold, or the perception of leg fatigue in patients with effort angina pectoris.
Sixteen patients with stable exertional angina pectoris and positive exercise tests (Bruce protocol with at least 1 -mm horizontal ST-segment depression) entered the stu@. No patient had chronic lung disease, valvular regurgitation, clinical heart failure or peripheral vascular disease. All patients gave written informed consent
